Kelly Thomas Patrick
SEC insider (Form 3/4/5 filer). CIK 0001410514. Chief Financial Officer at Xenon Pharmaceuticals Inc. (XENE). 4 reported Form 4/5 transactions since Sep 2024; latest on Oct 15, 2026. Located in BURNABY.
Companies Kelly Thomas Patrick has filed insider reports for
- Xenon Pharmaceuticals Inc. (XENE): Officer, Chief Financial Officer
Kelly Thomas Patrick
CIK: 0001410514
Transaction Breakdown
Open Market Buys (P)1 (25.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)1 (25.0%)
Derivative conversions
Awards (A)2 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
XENE
Xenon Pharmaceuticals Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Oct 15, 2026XENE
Xenon Pharmaceuticals Inc.
ExerciseDirect7.5K shares- - Sep 30, 2026XENE
Xenon Pharmaceuticals Inc.
PurchaseDirect15K shares at avg. $37.32$560K - Oct 15, 2025XENE
Xenon Pharmaceuticals Inc.
AwardDirectShare Option (Right to Buy)
225K shares- - Oct 15, 2025XENE
Xenon Pharmaceuticals Inc.
AwardDirectRestricted Share Units
30K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 15, 2026 | XENE Xenon Pharmaceuticals Inc. | Exercise | 7,500 | - | $0 | Direct |
| Sep 30, 2026 | XENE Xenon Pharmaceuticals Inc. | Purchase | 15,000 | $37.32 | $559,740 | Direct |
| Oct 15, 2025 | XENE Xenon Pharmaceuticals Inc. | Award Share Option (Right to Buy) | 225,000 | - | - | Direct |
| Oct 15, 2025 | XENE Xenon Pharmaceuticals Inc. | Award Restricted Share Units | 30,000 | - | - | Direct |
1-4 of 4 transactions